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Metabolism of complement factor D in renal failure. Factor D is an
essential enzyme of the alternative pathway of complement. Its plasma
concentration increases approximately tenfold in end-stage renal failure
(ESRF). To analyze its metabolism in humans, we injected purified
radiolabelled factor D into 5 healthy individuals and 12 patients with
various renal diseases or renal failure. Fractional metabolic rates
(FMR) and extravascular/intravascular distributions (EV/IV) were cal-
culated using a compartmental model. The FMR was very rapid in
normal individuals (mean 59.6 %/hr; range 74.1 to 50.5), significantly
diminished in the five patients with ESRF (5.7 %/hr; 7.0 to 2.8; P <
0.004), and correlated well with the creatinine clearance (r = 0.89; P <
0.001). The extrarenal catabolic rate was not modified in renal failure.
Despite a significant inverse correlation between plasma levels of factor
D and creatinine clearance Er = 0.68; P < 0.002], factor D levels were
not a sensitive indicator of renal function because the synthesis rate
(SR) varied widely from one individual to another (mean SR: 62.9
sg/kgIhr; 14.9 to 136.5). Factor D synthesis was not significantly altered
by renal function, and did not correlate with C-reactive protein,
suggesting that factor D is not an acute phase protein. The proportion of
intact factor D elimination in the urine was increased in patients with
tubular dysfunction (up to 15% compared to < 0.2% in normal individ-
uals) confirming that under normal circumstances factor D is filtered
through the glomerulus and catabolized by tubular cells. In renal failure
the EV/IV ratio was diminished (in normals: 8.5, 10.8 to 7.1; in ESRF:
2.4, 3.1 to 1.9; P < 0.004), indicating that accumulation of factor D was
more pronounced intravascularly. These findings suggest that in hu-
mans, factor D catabolism is very rapid and essentially renal. In renal
failure the several-fold increase in factor D concentration may be
responsible for enhanced alternative pathway activation, particularly in
the circulation.
In normal serum factor D is the rate limiting enzyme of the
alternative pathway of complement activation [1]. A sensitive
radioimmunoassay to measure factor D in plasma has been
developed only recently, and initial measurements indicated
that factor D levels were increased in renal failure. Patients with
end-stage renal failure (ESRF) had an approximately 10-fold
increase in factor D [2, 31. No factor D was detectable in the
urine of normal individuals or patients with nephrotic syn-
drome, however, large amounts of factor D were present in the
urine of a patient with the Fanconi syndrome. These findings
suggested that factor D is filtered through the glomerulus and
catabolized in the proximal renal tubules. In vivo nephron
microperfusion and in vitro perfusion of rat kidneys indicated
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also that factor D is handled initially via glomerular filtration
and catabolized after reabsorption by the proximal tubule [4}.
In vitro macrophages and a human hepatocyte-derived cell
line have been shown to synthesize factor D [5, 61. In vivo
factor D appeared not to be a protein of the acute phase
response [7, 8]. However synthesis, distribution and catabolism
of factor D have not been defined, thus limiting the understand-
ing of serum factor D levels in inflammatory states. Further,
these parameters may give insight into the biological role of
factor D under physiological and pathological conditions such
as renal failure.
The aim of this work was to define the metabolism of factor
D by injecting purified radiolabelled factor D in humans with
normal, decreased or absent renal function. The main findings
were that factor D was rapidly eliminated by the kidney in
normal subjects, and that factor D primarily accumulated in the
circulation in renal failure because of a striking modificaiton in
its bodily distribution. In contrast, extra-renal catabolic rate
and synthesis of factor D were not modified by impaired renal
function.
Methods
Control subjects and patients
Metabolic studies were performed in 5 healthy volunteers
(Table 1, subjects 1 to 5) and 12 patients with diminished or
absent renal function (patients 6 to 17). Patients 8, 12, 13 and 17
presented with tubular dysfunction as attested by lysozymuria.
Patients 6 to 10 (Table 2) were on long-term dialysis for
end-stage renal failure (ESRF); three were totally anuric. Pa-
tient 10 had membrano-proliferative glomerulonephritis type II,
0.29 g/liter of C3 (normal range: 0.7 to 1.3), and a circulating
nephritic factor. Patients 11 to 17 (Table 3) had intermediate
degrees of renal failure and were not on dialysis. Patient 12 had
received gentamicin (2 x 80 mg/day) for two weeks because of
sepsis, but his renal failure antedated the infectious episode.
Patients 13 and 17 had osteomyelitis and were on gentamicin (3
X 80 mg/day) for more than three weeks at the time of study.
Both had normal renal function before initiation of antibiotic
therapy. Patient 14 was severely nephrotic (membranous ne-
phritis): his urinary protein excretion ranged from 4.2 to 9 g/24
hr. Patients 15 and 16 were studied three months after renal
transplantation, and both were treated with cyclosporine at the
time of study.
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Table 1. Factor D metabolism in control subjects
Subject
Creatinine
clearance
ml/min
Synthesis 12 21 TSerum D FMR EV/IV rate q q
ag/ml % per hr ratio p.g/kglhr X 1O3/min
51q Glomerular
sieving coeff.
1 140 1.3 74.1 10.77 38,7 23 3.8 20 0.4 0.45
2 130 2.6 59.8 9.14 71.5 17 3.1 13 0.4 0.39
3 132 2.0 55.2 7.56 58.2 15 3.2 11 0.6 0.32
4 140 1.6 58.3 8.11 50.3 15 3.1 12 0.6 0.33
5 120 2.1 50.5 7.11 59.2 12 2.8 9.6 0.6 0.32
Mean 132 1.9 59.6 8.54 55.6 16 3.2 13 0.5 0.36
Table 2. Factor D metabolism in end-stage renal failure; patients on dialysis
Patient
Creatinine
clearance
ml/min
Synthesis 12Serum D FMR EV/IV rate q
pg/ml % per hr ratio 1Lg/kg/hr
21 T 51q q
x 103/min
6 0 20.6 7.0 2.7 92.3 9.1 3.2 — 0.5
7 0 18.1 6.6 1.4 106.8 5.8 3.9 — 0.9
8 <1 19.7 2.8 2.7 31.3 11 4.0 0.07 0.1
9 <1 14.8 6.5 3.1 67.9 13 4.1 0.1 0.3
10 <1 26.0 5.7 1.9 84.8 7.4 3.6 — 0.5
Mean <1 19.8 5.7 2.4 76.6 9.3 3.8 0.03 0.5
Table 3. Factor D metabolism in patients with reduced renal function (non-dialyzed)
Patient
Creatinine
clearance
mI/mm
Synthesis 12Serum D FMR EV/IV rate q
jig/mi % per hr ratio jig/kg/hr
21 T 51q q
X 1O3/min
11 6 3.2 5.6 2.3 14.9 23 10 0.6 0.2
12 11 4.8 21.1 2.7 58.2 10 4.2 2.5 0.7
13 18 5.1 25.1 7.2 68.4 8.1 1.5 3.4 0.3
14 23 9.7 25.9 1.2 136.5 9.4 8.5 3.5 0.2
15 51 2.0 41.7 6.5 45.8 10 2.4 7 0.6
16 52 1.7 44.5 6.5 43.4 12 2.9 8.2 0.4
17 70 1.1 75.8 42 41.7 9.8 0.7 19 0.5
Preparation of radiolabeiled factor D
Factor D was purified from the urine of a patient with Lowe's
syndrome (incomplete Fanconi's syndrome with congenital eye
and central nervous system defects) employing three successive
chromatographic steps: Bio-Rex 70 (Bio Rad Laboratories,
Richmond, Virginia, USA), hydroxyapatite HPLC and reverse-
phase HPLC [9]. Cultures of purified factor D were negative for
cytomegalovirus and human immunodeficiency virus (HIV).
This patient had no detectable hepatitis-B surface antigen and
no HIV antibodies in his plasma. The protein was radiolabelled
with '251-Bolton Hunter reagent (Amersham, Buckinghamshire,
UK) [10] to a specific activity of 3.7 pC/jig of factor D. Free
iodine was removed by gel filtration (Sephadex G-25, Pharma-
cia, Uppsala, Sweden) after having added 1% human serum
albumin (HSA, Armour, Eastbourne, UK) to the radiolabelled
factor D; the column was prewashed with phosphate buffer pH
7.2 containing NaCl 9 g/liter (PBS) and 1% HSA. Trichloroace-
tic acid precipitation (TCA, final concentration 10%) showed
that more than 95% of the radioactivity was protein-bound.
After Millipore filtration factor D was dialyzed against PBS,
aliquots were snap frozen in liquid nitrogen and stored at —80°C
until used. All manipulations were done using sterile buffers and
equipment. Sterility testing was done using standard bacterio-
logical methods and the preparation was pyrogen-free when
tested in four rabbits,
Purity and functional activity of radiolabelled factor D
Sodium dodecylsulfate polyacrilamide gel electrophoresis
(SDS-PAGE) [11] followed by autoradiography revealed only
one band of approximately 23 Kd (Fig. 1). In alternative
pathway hemolytic assays using guinea pig erythrocytes and
D-depleted serum, the functional activity of factor D was
unchanged by the labelling procedure [12, 13]. The plasma
disappearance curves of factor D were studied in three rabbits
after the injection of 10 to 20 jiCi '251-D. The animals were given
drinking water containing 0.1% of potassium iodide for three
days before the experiments. Blood samples were collected into
EDTA 10 m over four hours. After centrifugation, the protein
bound (TCA precipitable) and free radioactivity were measured
in plasma. In order to assess whether the factor D preparation
was denatured (or aggregated), studies were performed in two
rabbits to compare the elimination rates of unscreened and
biologically screened '251-D. The first rabbit injected with 21
pCi 1251D was bled after 30 minutes (10 ml); 5 ml of its plasma
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Fig. 1. SDS-PAGE of'251-labelled factor Dfollowed by autoradiogra-
phy. Markers for molecular weights are indicated (Kd). (a) Purified
'251-D, and (b) 100-fold concentrated urine from a normal subject: the
protein bound 1251 was intact factor D.
containing 0.6 pCi of '251-D were injected into a second rabbit
and the two disappearance curves were compared.
Human metabolic studies
These studies were approved by the ethical committee of the
Hôpital Cantonal Universitaire of Geneva. After informed
consent had been obtained, normal volunteers and patients
were injected with 7 to 15 Ci '251-D. Two milliliters of
potassium iodide 2% were given twice daily from the day before
the start of the study until its end. Blood samples were collected
in EDTA at 3 minutes, 5, 10, 20, 30, 60 minutes, and then at
hourly intervals during the first six hours; later sampling times
were chosen according to the rate of disappearance of '251-D,
that is, for 24 hours in normals or two to four days in patients
with renal failure. In dialysis patients (patients 6 to 10),
radiolabelled factor D was injected two hours after the end of a
dialysis session. Except for patient 6, the plasma disappearance
curves were not followed for more than 50 hours, that is, they
were studied between two dialysis sessions.
1251 in dialysis fluid was minimal (< 0.1% of the injected
dose), and thus did not affect the analysis of the results. The
plasma elimination curve was unaffected by dialysis in patient
6. The protein-bound radioactivity in plasma samples was
measured after TCA precipitation. Urine collections were done
for three to five days. Urinary protein-bound radioactivity was
determined by TCA precipitation of a 4 ml sample supplemented
with 20 mg/liter IgG as a carrier. Two hundred milliliters of
urine were concentrated to a volume of 2 ml by ultrafiltration
using a membrane with a cut-off of 10 Kd (Amicon). To show
that factor D was present in the retained radioactivity, samples
of concentrated urines were analyzed by SDS-PAGE followed
by autoradiography.
Factor D concentrations in blood and urine were determined
by a radioimmunoassay as previously described [2] and by a
hemolytic assay in sera that was sensitive enough to build a
dose response curve of activity [12, 13]. The specific hemolytic
activity of factor D was obtained from the ratio of hemolytic/
antigenic measurements. C-reactive protein (CRP) was mea-
sured by single radial immunodiffusion. Spontaneous in vitro
activation of C3 was measured in seven sera of patients
included in the present study: 50 l of serum was mixed with 50
pi of barbitone buffer containing NaCI 0.145 M, MgCI 0.83 mM,
and CaC1 0.25 ms, pH 7.2 (CFD, Oxoid), and incubated for 20
minutes at 37°C. The spontaneous activation of C3 was mea-
sured by crossed immunoelectrophoresis using monospecific
goat anti-human C3 antiserum (Miles) [13]. In control experi-
ments, 50 pi of monoclonal mouse anti-human factor D anti-
body (M. Pascual, unpublished) was added to the mixtures
before incubation.
Compartmental tnode! used for the analysis of factor D
metabolism
The results were analyzed using a model with five compart-
ments for '251-D; 1) extravascular and 2) intravascular compart-
ments for '251-D; 3 and 4) urinary compartments for '251-D and
125J, respectively; 5) extra-urinary elimination compartment
(feces, saliva, etc.). The model was expressed in terms of a
system of five ordinary differential equations, with five un-
known parameters to be estimated (mainly the exchange rates
between compartments) (Fig. 2 and Appendix).
Differential equations of the model:
n
S1(t) = q1i S(t), i = 1, . . . , n,
j= I
where /n (=5) is the number of compartments, S1 the state
functions, q• the transfer rates (most of them 0) if i j, and
= — q1ji
The initial conditions of the system were given as a measured
initial dose into compartment 2. The fact that we expressed the
model as a closed compartmental system provided a practical
device for controlling the stability of the numerical computa-
tion, as the sum of all state functions had to remain constant (=
initial dose).
Calculations were run using the program BEWITCH (Estrei-
cher J, unpublished data) consisting of an optimizer based on
the Gauss-Newton-Marquardt algorithm [14] and an ordinary
differential equations' solver based on the Runge-Kutta type
method of Dormand and Prince [15].
Whereas the volumes of the compartments and the exchange
rates were treated as unknown parameters to be directly
computed by the optimization methods, the extravascular!
p
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Fig. 3. '251-D disappearance curve in experimental animals. Symbols
are: screened • and unscreened U preparations of '251-D showing
comparable plasma disappearance curves.
Results
Elimination in urine Extra urinary
elimination (res.
saliva, stomach, etc.)
Fig. 2. Compartmental model used for the analysis offactor D metab-
olism; q exchange rates between compartments (fraction/mm); 0:
compartments in which measures were made. Because in most individ-
uals q32 was very low, the total renal catabolism (T) was analyzed: T =
q32 + q42. Although this model has five compartments from the
mathematical point of view, it has only two bodily compartments
(intravascular and extravascular).
intravascular (EV/IV) ratios and the fractional metabolic rates
(FMR % of the intravascular pool of factor D lost per hour by
all mechanisms, that is, by renal and extrarenal catabolism)
were deduced by elementary algebra from the fitted values of
the exchange rates, using the following formulae that apply to
the particular context of the compartment structure:
EV/IV ratio =
q51FMR T + 12
q21 + q5,
V(q21 + q51 — + T) 4 q21 q12 — (q2, + q51 — q1 + T)
2 q21
An approximation for the glomerular sieving coefficient (USC)
of factor D in the five normal individuals was calculated from
the formula: factor D clearance/creatinine clearance, where
factor D clearance = T (fraction of the intravascular pool of
factor D disappearing into the urine/mm) x plasma volume (ml)
116].
Statistical analysis
When appropriate, linear correlation coefficients and the
Mann-Whitney test were used.
Initial experiments were designed to establish that factor D
was not altered after the Bolton-Hunter radiolabelling proce-
dure; the functional hemolytic activity of the radiolabelled
protein was 100% compared to purified unlabelled factor D. The
turnover characteristics of the unscreened and the screened
preparation of '251-D are shown in Figure 3; plasma disappear-
ance curves were similar. The screened preparation of '251-D
was cleared at a slightly reduced rate which could indicate a
small fraction of factor D denaturation or a small individual
variation of factor D catabolism as observed in two other
rabbits injected with the unscreened preparation. Thirty min-
utes after i,v. injection of '251-D remaining in the circulation was
not modified as judged by SDS-PAGE autoradiography.
Factor D metabolism in humans
Metabolic parameters of control subjects are shown in Table
1. The very high FMR of factor D (approximately 60%/br) was
explained essentially by fast urinary elimination (T). Most
factor D was catabolized in the kidney (75%) and the rest (25%)
was eliminated by other routes (extra-urinary elimination). The
rate of diffusion of factor D into the EV space was rapid (q12),
and the calculated EV/IV ratio indicated that a very large
fraction of the total amount of factor D was in the LV
compartment. Using the results obtained for urinary elimina-
tion, and considering that this elimination was due only to
glomerular filtration we calculated the USC for factor D. The
mean USC for the five normal subjects was 0.36, that is,
corresponding to a high filtration rate—approximately one third
of the clearance of creatinine.
The patients' results are shown in Tables 2 and 3. Those with
ESRF (Table 2) had very different metabolic results from the
control subjects; the FMR and the EV/IV ratios were signifi-
cantly reduced, respectively 10-fold (P < 0.004) and 4-fold (P C
0.004). Defective renal catabolism of factor D was not compen-
sated for by any increase in the extra-renal elimination rate
(q5l). The catabolism of factor D in the patient with mesangi-
ocapillary UN type II (patient 10) was similar to that in the other
four patients. The patients with reduced renal function (Table 3)
'II
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D-125l
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Fig. 4. Correlation between renal function and the fractional meta-
bolic rate (FMR) of factor D fr = 0.89, P <0.001]. Symbols are: ()
control subjects; (U) patients.
had metabolic parameters intermediate between normal sub-
jects and patients with ESRF.
The FMR and the EV/IV ratio correlated with creatinine
clearance (Figs. 4 and 5), however, the EV/IV ratios were well
above the expected values in the two patients in whom genta-
micin nephrotoxocity was very likely (patients 13 and 17).
Factor D synthesis was very variable from one individual to
another; this observation would explain why factor D levels in
serum were not sensitive indicators of renal function in patients
with creatinine clearance between 5 and 23 mllmin, although the
general correlation with serum creatinine was excellent (Fig. 6).
Factor D synthesis did not correlate with plasma CRP concen-
tration which was increased in five patients. There was no
significant change in the specific hemolytic activity of factor D
in renal failure.
In normal subjects less than 0.2% of the radioactivity recov-
• F.!0
0 I
0 20 40 60 80 100 120 140
Creatinine clearance, rn//minute
Fig. 6. Relation between creatinine clearance and serum factor D
levels. Symbols are: (LI) control subjects; (•) patients (insert: relation
between factor D and serum creatinine; the white square represents the
five control subjects).
ered in the urine was protein-bound. When the urine samples of
two normal subjects were concentrated 100-fold it was possible
to show by SDS-PAGE autoradiography that this minimal
amount of protein-bound radioactivity was '251-D (Fig. 1). In
contrast, the urine of patients with lysozymuria (patients 8, 12,
13, 14 and 17) contained significantly more protein-bound
radioactivity (respectively 15%, 12%, 2.2%, 14.5% and 1%)
which was shown to be intact '251-D as well. The presence of
factor D in the urine was confirmed by radioimmunoassay in the
three patients with more than 10% protein-bound I25J
To see whether alternative pathway activation of C3 might be
enhanced in renal failure, we measured the spontaneous in vitro
activation of C3 in serum incubated at 37°C for 20 minutes. The
percentage of C3 converted to C3c was higher in four sera of
patients with renal failure than in three normal sera (mean
conversion: 40% vs. 19%, Mann-Whitney U test, P < 0.05).
This conversion was abrogated (3%) in the presence of
monoclonal mouse anti-factor D antibodies, indicating that it
was due to alternative pathway activation.
Discussion
This study defines the basis for the manyfold increase in
factor D concentration observed in patients with renal failure.
In normal individuals, in steady state the catabolism of radio-
labelled factor D was mainly renal (75%). In patients without
renal function the elimination rate of factor D was reduced
approximately 10-fold, thus explaining the increased plasma
levels. Neither the extra-renal catabolic rate (q51) nor the
synthesis rate were modified significantly by renal failure. The
results obtained indicated also that the synthesis rate of factor
D was variable from one individual to another, precluding the
use of factor D level in blood as a sensitive marker for renal
function in clinical practice. Finally, in renal failure factor D
accumulation was mainly intravascular.
Factor D is a glycoprotein of 23.5 Kd with an isoelectric point
of 7.4 [17, 18]. The elimination of factor D was comparable to
that of other molecules of similar molecular weight [16, 19—21].
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Such medium sized proteins are poorly retained by the glomer-
ular membrane, their USC being around 0.5. A calculated
estimation of the USC for factor D was 0.36, which is in the
expected range. Indeed the correlation between the FMR of
factor D and creatinine clearance was excellent. Sanders et al
have shown, using in vivo nephron microperfusion studies and
in vitro whole rat kidney perfusions, that factor D is reabsorbed
by a saturable process in the proximal tubules where the protein
is degraded [4]. In humans, intact factor D was detectable in the
urine of a patient with defective proximal tubular function [3].
Here we could demonstrate that a small fraction of intact factor
D reached the urine in normals (0.2%). Increased factor D
elimination in the urine was demonstrated in patients with
lysozymuria, and again such factor D was intact. In rabbits,
'25I-factor D was shown not to be fragmented in the circulation
in vivo, suggesting that there is no extracellular cleavage of
factor D in vivo. Thus factor D degradation appears to be an
intracellular process occurring in renal tubular cells, and defec-
tive tubular function results in the urinary loss of the unmodi-
fied protein.
Various authors have found a good correlation between
factor D and creatinine levels in blood, and between factor D
levels and creatinine clearance. It has even been suggested that
factor D was a better indicator of renal function than creatinine
in patients with connective tissue diseases [7, 8]. While we
found similar good correlations, we would like to emphasize the
wide range of factor D synthesis rates which was responsible
for a suboptimal correlation between factor D levels and
creatinine clearance, particularly in patients with reduced func-
tion (Fig. 6). We could not identify any pathological process
responsible for an increase or a decrease in factor D synthesis.
No correlation was found between factor D synthesis and CRP
levels, indicating that factor D is probably not an acute phase
protein.
Total factor D synthesis in normal individuals was 1.33
mg/kg/day, which is on the same order of magnitude as CIq, CS
and Cl inhibitor synthesis, and 5- to 10-fold below C3, C4 and
factor H synthesis [22—28]. In clinical practice, it might be
beneficial to block complement activation in various circum-
stances, for example in septic shock before the onset of the
adult respiratory distress syndrome [29]. Complement inhibi-
tors, in particular inhibitors of factor D function, have been
developed in in vitro models [30]. Any attempt to block factor
D function in vivo should take into account the high synthetic
rate of factor D.
Factor D catabolism was not accelerated, that is, factor D
was not consumed, in the patient with a circulating nephritic
factor and continuous fluid phase alternative pathway activa-
tion; this observation confirms the multiple in vitro data that
have indicated absence of factor D consumption at the time of
alternative pathway activation [1, 311.
The analysis of the EV/IV ratio of factor D indicated that in
normal subjects factor D was predominantly extravascular
(EV/IV ratio = 8.5); since the EV/IV ratio of extracellular water
is lower (approximately 3 to 4) our result suggests that factor D
concentration is higher in the extravascular space than in
plasma. In contrast, in patients with ESRF the distribution of
factor D was comparable to the distribution of extracellular
water (EV/IV ratio = 2.4), that is, the concentration of factor D
is probably similar in plasma and in the extravascular space.
These observations may be explained by the fast filtration of
factor D through the glomerulus in normal subjects which
continuously reduces plasma factor D concentration, preclud-
ing equilibration of factor D concentrations across the vascular
walls.
The unexpectedly high EV/IV ratio found in the two patients
with gentamicin toxicity may be due to accumulation of factor
D in the renal tubular cells related to a decrease in the
lysozomal degradation processes described in this condition
[32, 33]. Indeed the model used to analyze factor D metabolism
does not discriminate between different extravascular compart-
ments.
These findings may be of physiological importance. First,
alternative pathway activation may proceed differently in plasma
and extracellular fluids; the absolute and relative concentra-
tions of the various proteins involved are different [23—27].
Indeed, from the metabolic studies of C3, B, and H it can be
estimated that the concentrations of these proteins are lower in
extravascular fluids than in plasma. Since the opposite was
observed for factor D it is likely that there is a relative excess of
factor D in the extravascular fluid under normal circumstances.
Second, in renal failure the 10-fold increase in plasma factor D
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concentration was not matched by a similar increase in factor D
concentration in the extravascular space. Thus, enhancement
of alternative pathway activity by excess factor D would occur
predominantly in the circulation in these patients. The prelim-
inary experiments presented here indicated that spontaneous
alternative pathway activation of C3 was enhanced in sera of
patients with renal failure. However, further studies are neces-
sary to clarify the role of excess factor D on alternative pathway
function.
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Appendix
Mathematical model
We tried to analyze the metabolism of factor D by means of
a compartmental model which had to meet the following re-
quirements:
—uniqueness (the same model structure had to be applied to all
cases);
—globality (for each case, all observations had to be simulta-
neously taken into account by a single set of equations and
unknown parameters);
—adequacy (all observations had to be satisfactorily fitted by
the model curves);
—minimality (the size of the model had to be as small as
possible, regarding the number of compartments as well as the
number of unknown parameters).
What is more, we imperatively required the model to describe
as closely as possible the already-known biological features of
factor D.
We started our attempt to fulfill these requirements with the
smallest possible model, increasing its complexity step-wise in
order to improve the adequacy of the data, until obtaining a
model fitting properly the measurements. Our criterium of a
proper model was a chi-square value computed on the basis of
an assumed Poisson-distribution of the radioactive countings.
As an illustration, Figure 7 shows model curves fitted to
measured data, respectively in blood and urine, for subject 1.
Mathematical methods
Our problem is as follows:
given a system
y'=f1(t,y1 ,ym,xi x),il m
of m differential equations with n unknown parameters x1
x, and a series of data points (ti, t, a, pj) , j 1 N,
where t represents the observed value at time t, with error 0)
and a function expressing the model value to be compared to
the corresponding observed value, we have to determine the
parameters x1 , x in a way such as
G(x1 x1):
N
= {[/ij(tj, Yi y,,, x1 x) — J]/o)}2 = minimum.j= I
In the particular case of a Poisson-distribution,
crj=\/ andG=Xmn2.
Where the minimum is reached, the partial derivatives must
vanish:
Hk: = --- = {[(tj, y1, . . . , y, X x) —
js(tj, y1 ym' X1, . . . , x)
k=l n.
/0) = 0
If we now fix arbitrarily initial values to the parameters x1,.
x, the above equation allows to determine the x1 by the
Newton's method in n variables:
= x1 — w,
where w are solutions of the linear equation
n
= Hk.
1=1 ox1
Formally, the partial derivatives of the Hk are easy to
formulate:
OHk N N Ojj /= + [(pj — )/o] / 03,
Ox1 Ox, OXk j=I
but the computation of the second term above is numerically
time consuming if some precision has to be reached, since it
involves a second derivative.
We followed Marquart's idea, which was simply to discard
this second term, as the whole method is known to work well
only in the neighborhood of the solution, where the second term
is negligible in comparison with the first one. Additionally and
surprisingly, the method thus described is more stable in
general, as the matrix
(OHk
\, oxi
is now symmetric and can therefore be handled with more
powerful numeric linear methods than the general ones.
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After having obtained the first corrections w1, the whole
process is repeated with the new set of values for the unknown
parameters (x1 = x, — w1), as many times as needed to achieve
sufficient precision.
As such a method consists of embedded algorithms, each of
which may be time consuming, it is extremely sensible to make
use of fast numerical methods at each stage of the computa-
tional process.
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